BioXcel Therapeutics Inc (NASDAQ:BTAI)

12.25
Delayed Data
As of May 27
 +0.71 / +6.15%
Today’s Change
9.08
Today|||52-Week Range
39.00
-39.74%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$342.5M

Company Description

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Contact Information

BioXcel Therapeutics, Inc.
555 Long Wharf Drive
New Haven Connecticut 06511
P:(475) 238-6837
Investor Relations:

Employees

Shareholders

Mutual fund holders34.38%
Individual stakeholders32.21%
Other institutional17.32%

Top Executives

Vimal D. MehtaPresident, Chief Executive Officer & Director
Richard I. SteinhartChief Financial Officer & Vice President
Frank D. YoccaChief Scientific Officer & Senior Vice President
Vincent J. O'NeillChief Medical Officer & Senior Vice President
Javier RodriguezSecretary, Chief Legal Officer & Senior VP